Thanks to autoworkers, baristas, and some Biden administration agencies
CMS
Posted inHealth and Social Policy
Where Does Medicare Go From Here: Profit-Driven Chaos or Patient-Centered Community?
After covering the Medicare privatization crisis for over two years, an investigative reporter takes a step back and examines what’s at stake.
Posted inHealth and Social Policy
Our Uniquely American Drug Shortages
More drugs are in short supply than ever before. We’ve known the reason why for a long time: monopolistic middlemen.
Posted inHealth and Social Policy
Between You and Your Doctor: How Medicare Advantage Care Denials Affect Patients
As UnitedHealth racks up unprecedented profits, the people it insures battle for care.
Posted inHealth and Social Policy
Company Behind Joe Namath Medicare Advantage Ads Has Long Rap Sheet of Misconduct
The firm formerly known as Benefytt pocketed millions selling sham insurance to seniors and other consumers.
Posted inHealth and Social Policy
The Great Medicare Advantage Marketing Scam
How for-profit health insurers convince seniors to enroll in private Medicare plans
Posted inMoney, Politics, and Power
Democrats Could Score Big by Blocking This Revolver
Demetrios Kouzoukas’s nomination battle offers the perfect opportunity for Democrats to prove themselves to voters.
Posted inHealth and Social Policy
The Medicare Advantage Trap
In 46 states, once you choose Medicare Advantage at 65, you can almost never leave.
Posted inHealth and Social Policy
We May Not Negotiate Prices for Ten Drugs After All
Rules that exempt drugs from Medicare negotiation if there’s ‘meaningful’ generic competition could whittle down the effect of the program.
Posted inHealth and Social Policy
Medicare Price Negotiation: Ten Drugs That Made the List, and Ten That Should Have
Advocates were thrilled that Medicare will negotiate the price of several insulins. But other high-profit drugs are protected by the new program’s rules.